Amelia is a Data Scientist at the Bennett Institute focusing on the OpenSAFELY research platform. She is interested in improving how routinely-collected health data can be used to deliver urgent answers on key clinical and public health questions. Her work to date has mostly focused on building exploratory inference models and developing predictive models using large scale data to answer clinically relevant questions and aid future decision making processes. Amelia has a BSc in Mathematics and Sports Science from the Loughborough University and an MSc in Mathematical Sciences and a PhD in statistics/pharmacoepidemiology from the University of Bath.
Papers by Millie Green
- Impact of COVID-19 on recorded blood pressure screening and hypertension management in England
- Therapeutics Dataset from COVID-19 Medicine Delivery Units in England
- The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
- OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents
- Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England
- OpenSAFELY: a platform for analysing electronic health records designed for reproducible research
- Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home
- Eleven key measures for monitoring general practice clinical activity during COVID-19
- Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY
- Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages
- Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings
- Factors associated with COVID-19 vaccine uptake in people with kidney disease
- Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community
- Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose
- Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England
- Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England
- Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies
- Safety of COVID-19 vaccination and acute neurological events
- Potentially inappropriate prescribing of DOACs to people with mechanical heart valves
- Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic
- Trends and clinical characteristics of COVID-19 vaccine recipients